New York Blood Center, Inc.
$184.6K 74 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Neo Spine USA, Inc.
Neo Spine USA, Inc. reported $184,539.06 across General Payments, Research, and Ownership to 95 physicians and teaching hospitals across 95 transactions.
- $184.5K Below-median payer
- All-tracks total
- 95 Below-median volume
- Transactions
- 95 Below-median reach
- Recipients
- +$8.7K
- General Payments vs PY2023
Neo Spine USA, Inc. reported $184,539.06 across all CMS Open Payments tracks (General + Research + Ownership) to 95 physicians and teaching hospitals in Program Year 2024 - ranking #1027 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $184,539.06, averaging $1.9K per recipient.
Neo Spine USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer neo-spine-usa-inc Neo Spine USA, Inc.
$184.5K · #1027/1,925 · 0.0% industry · PY2024
- TOT $184.5K
- RANK #1027
- SHARE 0.0%
- TXN 95
- RCP 95
- CAT 3
- GEN $184.5K
- ΔGEN +$8.7K
- TOP1 41.2%
- PY 2024
Volume peers
Nearest volume peer: New York Blood Center, Inc. ($184.6K)
Neo Spine USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Neo Spine USA, Inc.'s CMS-reported General Payments increased by $8.7K (+4.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NEO SPINE USA, INC.PY2023: NEO SPINE USA, INC.PY2024: Neo Spine USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $175,855.21
- PY2024
- $184,539.06
What the Data Shows for Neo Spine USA, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Neo Spine USA, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
70 transactions worth $81.8K make "Food and Beverage" the top general-payment category in the 3-category breakdown below, 44.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Neo Spine USA, Inc.'s 3-category general-payment breakdown at $81.8K, 44.3% of the reported total.
How Neo Spine USA, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $81.8K | 70 | 44.3% |
| Consulting Fee | $54.6K | 10 | 29.6% |
| Travel and Lodging | $48.2K | 15 | 26.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $164,771.51 (89.3%) of $184,539.06 in this company's General Payments records across 45 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Neo Spine USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Vivek A Mehta
$75,967.42 across 5 reported transactions
- 2
Steven M Spitz
$49,923.86 across 20 reported transactions
- 3
Joseph D Ciacci Mr
$24,666.74 across 7 reported transactions
- 4
John D Attenello Mr
$9,210.70 across 1 reported transactions
- 5
Robert K Eastlack Mr
$5,002.79 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Neo Spine USA, Inc. ranks #1027 of 1,925 by total payments (bottom 47% by spend) but is notably more concentrated than that alone would suggest -- #623 of 1,838 by HHI (top 34% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Eisai Co., Ltd. : $54.3K total payments, HHI 2691
- Bonebridge Inc. : $41.9K total payments, HHI 2676
- Spinecraft, LLC : $201.8K total payments, HHI 2668
- Longeviti Neuro Solutions LLC : $59.9K total payments, HHI 2668
- Aurobindo Pharma USA, Inc. : $120.1K total payments, HHI 2662
- Baylis Medical Technologies Inc. : $71.7K total payments, HHI 2658
- Neo Spine USA, Inc. (this company) : $184.5K total payments, HHI 2657
- United Medical Systems (DE), Inc. : $704.50 total payments, HHI 2641
- McKesson Sourcing Services, Inc. : $32.7K total payments, HHI 2633
- iCAD, Inc : $277.8K total payments, HHI 2628
- Aprecia Pharmaceuticals, LLC : $72.49 total payments, HHI 2625
- Carl Zeiss Meditec Cataract Technology Inc. : $122.7K total payments, HHI 2624
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Neo Spine USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Neo Spine USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Neo Spine USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Marius Pharmaceuticals, Inc
$184.4K 23 recipients
Compare payment profiles
RedDress USA, Inc.
$184.0K 225 recipients
Compare payment profiles
Ultrasight Inc
$183.8K 54 recipients
Compare payment profiles
VEO Ophthalmics
$185.8K 0 recipients
Compare payment profiles
Accord Healthcare, Inc.
$183.2K 4,160 recipients
Compare payment profiles
Put this to use
Neo Spine USA, Inc. ranks #1027 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Neo Spine USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.